Impairment of Cd4+ T Cell Responses during Chronic Virus Infection Prevents Neutralizing Antibody Responses against Virus Escape Mutants by Ciurea, Adrian et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2001/02/297/09 $5.00
Volume 193, Number 3, February 5, 2001 297–305
http://www.jem.org/cgi/content/full/193/3/297
 
297
 
Impairment of CD4
 
1
 
 T Cell Responses during Chronic 
Virus Infection Prevents Neutralizing Antibody Responses 
against Virus Escape Mutants
 
By Adrian Ciurea, Lukas Hunziker, Paul Klenerman,
Hans Hengartner, and Rolf M. Zinkernagel
 
From the Institute for Experimental Immunology, University Hospital, CH-8091 Zürich, Switzerland
 
Abstract
 
We have shown previously that neutralizing antibodies (nAbs) are important contributors to
the long-term immune control of lymphocytic choriomeningitis virus infection, particularly if
cytotoxic T cell responses are low or absent. Nevertheless, virus escape from the nAb response
due to mutations within the surface glycoprotein gene may subsequently allow the virus to per-
sist. Here we show that most of the antibody-escape viral mutants retain their immunogenicity.
We present evidence that the failure of the infected host to mount effective humoral responses
 
against emerging neutralization-escape mutants correlates with the rapid loss of CD4
 
1
 
 T cell
responsiveness during the establishment of viral persistence. Similar mechanisms may contrib-
ute to the persistence of some human pathogens such as hepatitis B and C viruses, and human
immunodeficiency virus.
Key words: persistent infection • lymphocytic choriomeningitis virus • T helper cells • 
humoral responses • viral evasion
 
Introduction
 
Strong CD8
 
1
 
 CTL responses characterize the initial im-
munosurveillance of infections with poorly or noncyto-
pathic viruses such as hepatitis B and C viruses, HIV, and
the murine RNA virus lymphocytic choriomeningitis virus
(LCMV
 
1
 
 [1–3]). Nevertheless, this initial clearance of vire-
mia by CD8
 
1
 
 CTLs does not always prevent the establish-
ment of a chronic infection. Besides CTLs, neutralizing
Abs (nAbs) in association with other noncytolytic factors
(IFN-
 
g
 
, TNF-
 
a
 
, and chemokines) play a crucial role in
controlling persisting virus infection (4–8). However, virus
escape from the nAb response during chronic infections
does occur and may contribute to viral persistence (9). We
have recently demonstrated in a model system that low
CTL activity during LCMV infection facilitates the detec-
tion of neutralization-escape virus variants (10). Escape was
due to single point mutations within the genes coding for
the envelope glycoprotein (GP)-1. The ensuing amino
acid changes affect the conformation of the neutralizing
epitope (11).
The following questions have been further addressed in
this study. (a) Are the envelope GPs of nAb-escape LCMV
variants less immunogenic? (b) How quickly and efficiently
are nAbs generated against emerging escape variants? (c)
Do variants evolve that are in general neutralization resis-
tant? (d) Is the impairment of nAb responses due to dele-
tion or anergy of virus-specific T helper cells?
We studied the nAb response during a long-term infec-
 
tion of CD8
 
2
 
/
 
2
 
 mice with LCMV, strain WE (12). Due to
the absence of CTLs in these mice, augmented virus pro-
duction occurs, which is transiently controlled by poly-
clonal nAbs in the blood and only to a limited extent in
solid organs (10). The results indicate that the broadening of
nAb responses against emerging neutralization-resistant vi-
rus variants in this high viremia model infection was mainly
limited by a decrease and eventual loss of virus-specific
CD4
 
1
 
 T cell responses. Changes in replication properties or
a decreased immunogenicity of some virus variants may ad-
ditionally contribute to virus persistence.
 
Materials and Methods
 
Mice and Viruses.
 
CD8
 
2
 
/
 
2
 
 mice (13), LCMV-GP61-80–spe-
cific CD4
 
1
 
 TCR transgenic (tg) SMARTA mice (14), and con-
trol C57BL/6 (B6) mice were obtained from the Institut für
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Labortierkunde (University of Zürich, Zürich, Switzerland). In
certain experiments, B6 mice were in vivo depleted of CD8
 
1
 
 T
cells by treatment with a tested anti-CD8 monoclonal Ab on days
3 and 1 preceding the infection, as described (10). The degree of
depletion was always 
 
.
 
95% in blood and spleen. All animals
were kept under specific pathogen-free conditions.
LCMV strain WE originally was obtained from F. Lehmann-
Grube (Heinrich Pette Institut, Hamburg, Germany) and propa-
gated on L929 cells. Mice were infected with 2 
 
3 
 
10
 
6
 
 PFU of
LCMV-WE intravenously. LCMV titers in blood or virus titers
of stock solutions were determined with an immunological focus
assay (15).
LCMV nAb–escape variants were isolated from the blood of
CD8
 
2
 
/
 
2
 
 mice (120 and 240 d after infection), grown on MC57
cells for 48 h, and subsequently plaque purified two times in vitro
as described (16). For de novo infections, mice were immunized
with 2 
 
3 
 
10
 
4
 
 PFU of selected virus variants intravenously.
Vesicular stomatitis virus (VSV) Indiana (VSV-IND; Mudd-
Summers isolate) was originally obtained from Dr. D. Kola-
kovsky (University of Geneva, Geneva, Switzerland) and was
grown on BHK21 cells. Mice were infected with 2 
 
3 
 
10
 
6
 
 PFU of
VSV-IND intravenously.
 
Neutralizing Activity.
 
Neutralizing activity against LCMV was
measured in a focus reduction assay (15). The neutralizing titer
was defined as the dilution causing half-maximal reduction of
plaques of LCMV when compared with the same amount of vi-
rus incubated with control sera from uninfected mice. VSV neu-
tralization assay was performed as described (17). The highest di-
lution of serum that reduced the number of plaques by 50% was
taken as the titer. To determine IgG Ab titers, undiluted serum
was pretreated with 0.1 M 
 
b
 
-mercaptoethanol.
 
Adoptive Transfers.
 
Spleen cell suspensions were prepared
from naive SMARTA tg mice previously in vivo depleted of
CD8
 
1
 
 T cells by treatment with anti-CD8 monoclonal Abs. 5 
 
3
 
10
 
5
 
 SMARTA splenocytes were transferred intravenously into
recipient B6 or CD8
 
2
 
/
 
2
 
 mice, 1 d before infection with 2 
 
3 
 
10
 
6
 
PFU of LCMV-WE. Both SMARTA and CD8
 
2
 
/
 
2 
 
mice have a
pure B6 background. Clonal expansion and disappearance of
transferred tg cells in the blood of recipients were monitored by
FACS
 
®
 
 analysis using TCR V
 
a
 
2 and V
 
b
 
8.3 monoclonal Abs.
 
Intracellular IFN-
 
g
 
 Staining.
 
Splenocytes (10
 
6
 
 cells/well in 96-
well plates) were stimulated in vitro with media or with the im-
munodominant LCMV-specific peptide GP61-80 (1 
 
m
 
g/ml).
Brefeldin A (Sigma-Aldrich) was added after 1 h of culture. After
a 5-h stimulation, the cells were harvested, washed once in PBS
containing 2% FCS, and stained with PE-conjugated anti-CD4
monoclonal Abs (Caltag) for 30 min at 4
 
8
 
C. After washing of un-
bound Ab, the cells were fixed with PBS/4% paraformaldehyde
for 10 min and then permeabilized with PBS/0.1% Saponin
(Sigma-Aldrich). For intracellular staining, FITC-conjugated
anti–IFN-
 
g
 
 monoclonal Abs were used and incubated with the
cells for 30 min at 4
 
8
 
C. After washing twice with PBS/0.1% Sa-
ponin, the cells were resuspended in PBS containing 2% FCS and
analyzed using a FACScan™ (Becton Dickinson). To control for
nonspecific intracellular staining, parallel samples of stimulated
and permeabilized CD4
 
1
 
 T cells were stained with FITC-conju-
gated isotype-matched monoclonal Abs of irrelevant specificity,
which did not result in any staining signal.
 
Molecular Analysis.
 
Total RNA of MC57 cells infected either
with LCMV-WE wild-type (wt) or with variant virus isolates for
48 h at an initial multiplicity of infection of 0.01 was extracted by
using RNeasy kit (QIAGEN). Reverse transcription PCR was
performed using the LCMV-GP1–specific primers R1 (5
 
9
 
-
 
1037
 
TCG TAG CAT GTC ACA GAA CTC TTC
 
1014
 
-3
 
9
 
) for re-
verse transcription and the primer pairs 001/R1 and 001/RC1
(001, 5
 
9
 
-
 
1
 
CGC ACC GGG GAT CCT AGG CTT
 
21
 
-3
 
9
 
; RC1,
5
 
9
 
-
 
965
 
GAG CTC TGC AGC AAG GAT CAT CC
 
942
 
-3
 
9
 
) for
Hot Start PCR amplification. PCR products were sequenced by
automated 
 
Taq 
 
cycle sequencing (
 
Taq
 
 Dye Deoxy Terminator
Cycle Sequencing kit; Applied Biosystems; Bio-Rad Laborato-
ries) using the primers 001 and RC1.
 
Results
 
NAb Responses against Emerging nAb-escape Virus Mu-
tants.
 
Virus titers as well as nAb titers were sequentially
determined in the blood of five LCMV-WE–infected
CD8
 
2
 
/
 
2
 
 mice (animals M7–M11) for up to 240 d. As re-
ported previously (10), nAb-mediated control of viremia,
attained within 50–60 d after infection, was only transient
and virus reappeared in the blood 2–4 wk after initial con-
trol (Fig. 1). This occurred despite the presence of relatively
high titers of nAbs (Fig. 2, filled circles). Viremia was not
controlled at later time points in CD8
 
2
 
/
 
2
 
 mice (Fig. 1),
suggesting that induction of new nAb responses against
emerging neutralization-resistant virus variants had failed.
To assess long-term virus-specific humoral and T helper re-
sponses in these mice, we next characterized the virus vari-
ants emerging in vivo. Virus was isolated from the blood of
mice M7–M11 after the recrudescence of viremia (day
120). Sequence analysis of the gene encoding the envelope
GP1 of LCMV isolates revealed amino acid alterations of
the predominant viral clone (WE-M7 to WE-M11) within
the bulk virus isolated from each animal (at least 5 out of
8–10 independent clones; Table I). One to three base pair
exchanges per GP1 gene were identified, leading to amino
acid substitutions within the three regions of GP1 that have
been shown to correlate with virus escape from the nAb re-
sponse (10). These mutations affected the efficiency of vari-
ant virus neutralization by polyclonal hyperimmune serum
(pooled from B6 mice immunized with LCMV-WE) and
by LCMV-WE-GP1–specific mAb (data not shown).
We next performed autologous serum neutralization as-
says with virus variants WE-M7 to WE-M11 and with
Figure 1. Transient control of viremia in CD82/2 mice. CD82/2 mice
(animals M7 to M11; d) and control B6 mice (s) were infected with
2 3 106 PFU of LCMV-WE-wt intravenously, and sequential blood
samples were analyzed for virus titers. Data shown are the mean for five
mice 6 SEM. 
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LCMV-WE-wt (Fig. 2). The strong initial nAb response
against the immunizing virus (LCMV-WE-wt) peaked
around day 75 and declined very slowly. In contrast, low or
no neutralizing activity was detected against virus escape
variants at all time points tested. Hence, these variants have
indeed escaped the original nAb response, and failed to in-
duce specific nAbs over a period of 120 d (Fig. 2). The fail-
ure of the variants to induce an effective nAb response
could have several reasons. Theoretically, we cannot ex-
clude that novel nAbs are generated, as this could be
masked by outgrowth of newly evolving escape mutants.
We therefore sequenced day 240 isolates from the blood of
three test animals (M7, M8, and M9). The GP1 sequence
of the predominant clone (at least 5/8 isolates) is shown in
Table I. No sequence changes were observed when viral
isolates derived on day 120 and 240 after infection were
compared in mice M7 and M9, respectively. In mouse M8,
the predominant virus clone had one additional amino
acid–changing mutation at position 122 on day 240, com-
pared with day 120. Nevertheless, a clone with this geno-
type was already present in the viral quasispecies on day
120 (1/8 clones; data not shown). Overall, the escape mu-
tants were relatively stable, which suggests the absence of a
specific newly induced immune selection pressure. Selec-
tion of predominant virus variants within the quasispecies
at late time points, as seen in animal M8, might therefore
be influenced by viral fitness (18).
Figure 2. NAb responses against immunizing LCMV-WE-wt and
emerging LCMV variants in five individual CD82/2 mice. (A–E) Five
CD82/2 mice (animals M7–M11) were infected with 2 3 106 PFU of
LCMV-WE-wt. Sequential serum samples were tested for neutralizing
(Neutr.) activity against LCMV-WE-wt (d) and against the predominant
LCMV variant (WE-M7 to WE-M11; s) isolated from the correspond-
ing mouse after viral reemergence on day 120 after infection (see charac-
terization of variants in Table I). a, anti.
 
Table I.
 
LCMV-WE nAb-escape Variants Contain Amino
Acid–changing Point Mutations within the Sequence Coding for the 
Envelope Protein GP1 (Amino Acids 59–262)
 
Amino acid substitution
at indicated position
Day Virus 122 177 182 211 212
Mouse 0 LCMV-WE-wt Phe Pro Ser Ala Gly
M7 120 WE-M7 Arg Asp
240 Arg Asp
M8 120 WE-M8 Asn
240 Ser Asn
M9 120 WE-M9 Ser Asp
240 Ser Asp
M10 120 WE-M10 Ser Leu Thr
M11 120 WE-M11 Asn Thr
Virus was isolated from the blood of five CD8
 
2
 
/
 
2
 
 mice (M7 to M11)
120 and 240 d after infection with 2 
 
3 
 
10
 
6
 
 PFU of LCMV-WE and
double plaque purified. Positions of alterations in deduced amino acid
residues of the envelope GP1 of the predominant viral clone (at least 5
out of 8–10 clones) from each animal are shown.
Figure 3. Induction of specific CD41 T cell unresponsiveness in
LCMV-infected CD82/2 mice. B6 mice (triangles) and CD82/2 mice
(circles) were infected with 2 3 106 PFU LCMV-WE intravenously. (A)
Splenocytes from the indicated days after infection were stimulated in
vitro with the immunodominant LCMV class II–restricted epitope
(GP61–80; filled symbols) or with no peptide (open symbols), and the
percentage of peptide-specific CD41 T cells expressing intracellular
IFN-g was then assessed. (B) 5 3 105 splenocytes from in vivo CD8-
depleted, LCMV-GP61-80–specific CD41 TCR tg SMARTA mice (B6
background) were adoptively transferred intravenously to recipient B6
mice that were either infected with LCMV-WE 1 d later (filled symbols)
or were not infected (open symbols). The percentage of tg CD41 T cells
(TCR Va21; Vb8.31) in the blood was then sequentially determined by
FACS® analysis. Data shown are the mean for four mice 6 SEM. 
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Loss of CD4
 
1
 
 T Cell Responsiveness Precedes the Emergence
of nAb-escape Virus Mutants.
 
Failure of the hosts to elicit
new nAb responses against emerging nAb-escape virus
variants could be due to insufficient CD4
 
1
 
 T helper re-
sponses at late time points. This could be the consequence
of CD4
 
1
 
 T cell unresponsiveness induced during establish-
ment of persistent infection (19), T helper epitope varia-
tion, or a decrease of infected CD4
 
1
 
 T cells.
LCMV-specific CD4
 
1
 
 T cell responses were compared
between LCMV-infected CD8
 
2
 
/
 
2
 
 mice, which show a
high and sustained viremia, particularly in solid organs, and
control B6 mice, which rapidly control the virus (10; Fig.
1). We monitored the number of splenic CD4
 
1
 
 T cells
specific for the LCMV-immunodominant epitope GP61–
80 and expressing intracellular IFN-
 
g
 
 after antigenic stimu-
lation at different time points after infection (Fig. 3 A). In
agreement with previous studies (20–22), this response
peaked at day 9 in control B6 mice (
 
z
 
3% of CD4
 
1
 
 T cells)
and decreased to 0.4% by day 50. This percentage was sta-
ble in the memory phase (up to 240 d). By contrast, only
0.6% of CD4
 
1
 
 T cells stained positive for intracellular IFN-
 
g
at the peak of the response in CD82/2 mice. This per-
centage rapidly dropped to background levels by day 20. In
CD82/2 test animals M7 to M11, only background levels
of virus-specific CD41 T helper activity were detected on
day 240 (Fig. 3 A), irrespective of the ability of the mice to
produce low or high nAb titers against the immunizing
LCMV-WE-wt virus (Fig. 2). We were not able to moni-
tor an additional T helper response against the nucleopro-
tein NP309–328 epitope because on day 8 after infection,
frequencies of specific CD41 T cells were below back-
ground levels in LCMV-WE–infected CD82/2 mice. To
ascertain that the responses measured in the in vitro assays
were not affected by the absence of CD81 T cells, we
performed the following control experiment. LCMV-WE–
immune B6 mice (70 d after infection) were either depleted
of CD81 T cells or left untreated. We then evaluated
the number of splenic LCMV-specific, IFN-g–expressing
CD41 T cells. Similar percentages of GP61-80–specific
CD41 T cells were measured in the spleens of mice of the
two groups (data not shown). As indicated by sequence
analysis, failure to detect GP61-80–specific CD41 T cells
in CD82/2 mice was not due to epitope variation (Table I,
and data not shown).
As mentioned above, several factors could account for
the low levels of CD41 T cells in the high viremia CD82/2
model system. Loss of total CD41 T cell population due to
infection and/or immunopathology, specific unresponsive-
ness of the LCMV-specific T helper subset, but also a defi-
ciency in generating the initial response, have to be consid-
ered. To specifically study the effects of persistent high
viremia on CD41 T cell expansion, we performed adoptive
transfer experiments with LCMV GP61–80 epitope–spe-
cific splenocytes from in vivo CD8-depleted SMARTA
TCR tg mice. This approach allowed for monitoring of
the transferred LCMV-specific T helper cells via the tg
TCR Va and Vb chains (Fig. 3 B). Compared with B6
mice, clonal expansion of the transferred tg CD41 T cells
was compromised in LCMV-infected CD82/2 mice.
Moreover, we found that these cells disappeared more rap-
idly from the blood of recipient LCMV-infected CD82/2
mice. The tg CD41 T cells were still present in high num-
bers on day 16 in the blood of LCMV-infected B6 mice
and were still above background levels by about day 40.
No obvious differences were seen in uninfected B6 and
CD82/2 mice, suggesting that the effects seen were a con-
sequence of high level viral replication.
To investigate whether the reduction of LCMV-specific
T helper cells was due to an overall decline of the CD41 T
cell population in the high viremia model, we assessed the
absolute number of splenic CD41 T cells by flow cytome-
try before and after LCMV infection. No depletion of the
general CD41 T cell pool was detected after infection of
CD82/2 mice with LCMV-WE (Fig. 4).
To test whether loss of CD41 T cells during high vi-
ral replication was restricted to LCMV-specific cells or
whether unrelated, non-LCMV responses were also af-
fected, we evaluated CD4 T cell help against VSV. VSV
induces a very early neutralizing IgM Ab response that is
largely T cell help independent; the subsequent IgM switch
Figure 4. The CD41 T cell population is not depleted during LCMV
infection. B6 mice and CD82/2 mice were infected with 2 3 106 PFU of
LCMV-WE. Splenocytes at various time points after infection were
stained for CD4. Numbers of CD41 T cells were determined by flow cy-
tometry. Data shown are the mean of three mice per group 6 SEM.
Figure 5. Functional VSV-
specific T cell help in LCMV-
WE infected CD82/2 mice. B6
mice (triangles) and CD82/2
mice (circles) infected with 2 3
106 PFU of LCMV-WE 240 d
previously (B), as well as naive
control animals (A), were immu-
nized with 2 3 106 PFU of
VSV-IND. Sequential serum
samples were obtained for quan-
titation of VSV-neutralizing
(neutr.) IgM Ab titers (filled
symbols) or IgG Ab titers (open
symbols), distinguished from
IgM by reduction with 0.1 M of
b-mercaptoethanol. The results
are given as the mean 6 SEM of
three to four mice per group.301 Ciurea et al.
to IgG is in contrast strictly dependent on functional CD41
T cell help (23). CD82/2 and B6 mice, 240 d after LCMV
infection, and uninfected control animals were immunized
with 2 3 106 PFU of VSV-IND intravenously. Anti-VSV
IgM and IgG Ab titers were assessed in sequential serum
samples (Fig. 5, A and B). LCMV-infected CD82/2 mice
were able to switch their anti-VSV IgM Ab responses to
IgG, proving that functional VSV-specific CD41 T cell
help was present (Fig. 5 B). Hence, the time-dependent in-
duction of T helper unresponsiveness in CD82/2 mice was
LCMV specific.
Immunogenicity of nAb-escape Virus Variants. In addition
to insufficient CD4 T help, nAb responses against escape
viruses might be low as a consequence of decreased immu-
nogenicity of their envelope proteins. To study the immu-
nogenicity of nAb-escape variants in vivo, we have chosen
to use the model infection of mice depleted in vivo of
CD81 T cells by treatment with anti-CD8 monoclonal
Abs. In contrast to CD82/2 mice, earlier virus control
through the antiviral activity of reappearing CTLs takes
place in this model (10). Therefore, due to the lower vire-
mia, less Ab is masked by excess antigen. Escape mutants
were tested in infections with 2 3 104 PFU, a dose avail-
able for all variants. Two isolates (WE-M10 and WE-M11)
persisted for longer periods in CD8-depleted mice,
whereas WE-M7, WE-M8, and WE-M9 were eliminated
with similar kinetics as LCMV-WE-wt (Fig. 6 A). In con-
trast to our previous study (10), in which neutralization-
resistant variants that showed enhanced persistence induced
lower autologous nAb titers, all variants studied here raised
autologous nAb responses similar to LCMV-WE-wt (Fig.
7, A–E). Interestingly, heterologous nAb titers against
LCMV-WE-wt in mice infected with variant viruses were
at least as high as autologous titers, demonstrating a broad
neutralizing response in these mice (Fig. 7, A–E).
To assess whether differences in immunogenicity are de-
pendent on the animal model used, we performed de novo
infection experiments with 2 3 104 PFU of WE-M7 iso-
late and LCMV-WE-wt in CD82/2 mice. Infection with
the variant strain was cleared with similar kinetics (within
60 d) as wt virus in these animals (Fig. 6 B). Moreover,
both variant and wt virus induced an equally strong neu-
tralization response (Fig. 7 F). Of note is that the nAb re-
sponse in CD82/2 mice was, for both wt and escape virus,
lower than in CD8-depleted mice.
Discussion
We have previously introduced a LCMV infection
model in CD8-deficient mice that is characterized by a
high persistent viremia, and that only transiently is con-
trolled by nAb, as neutralization-resistant variants are gen-
erated very rapidly (10). This model of prolonged absence
of CD81 T cells is reflected in several virus diseases in
which low or absent CTL activity during establishment of
persistent infections occurs. CTL responses may exhaust or
become unresponsive after overwhelming infection with
LCMV (24, 25), may physically or functionally disappear
during HIV-1 infection (26–28), and become scarce once
Figure 6. In vivo replication of nAb-escape variants. CD8-depleted B6
mice (A) and CD82/2 mice (B) were infected with 2 3 104 PFU of
LCMV-WE-wt or of the indicated nAb-escape LCMV variant (for
CD82/2 mice only variant WE-M7). Sequential blood samples were ob-
tained for quantitation of virus titers. Data shown are the mean of three to
four mice per group 6 SEM. The experiment shown in A was performed
twice with similar results.
Figure 7. Immunogenicity of LCMV-WE nAb-escape variants. (A–E)
Sequential blood samples from CD8-depleted mice infected with 2 3 104
PFU of five nAb-escape variants WE-M7 (A), WE-M8 (B), WE-M9 (C),
WE-M10 (D), and WE-M11 (E) were obtained for quantitation of nAb
titers against the immunizing virus (d) and of nAb titers against LCMV-
WE-wt (s). The dotted lines represent the autologous nAb response after
infection of CD8-depleted mice with an equivalent dose of LCMV-WE-
wt. The experiment was repeated in CD82/2 mice for variant WE-M7
(F). Data shown are the mean for three mice per group 6 SEM. Neutr.,
neutralizing.302 T Cell Unresponsiveness Facilitates Virus Escape from Antibody Responses
infection with hepatitis C virus is established (3). In addi-
tion, viral escape from CTL responses through selection of
mutations in the relevant epitopes has been documented
(29–32), and may even occur early in the course of infec-
tion (33, 34).
As documented here, several factors may allow the per-
sistence of emerging neutralization-resistant variants. A
weaker immunogenicity of the escape variants seems not to
be a general phenomenon, as most of the variants were able
to induce autologous nAb responses after de novo infec-
tions similar to wt LCMV-WE. However, we observed an
asymmetric pattern of cross-reactivity between neutralizing
responses induced by wt and escape virus isolates. Whereas
the original wt strain induced a response against itself but
not against the emerging escape variants, the mutant viruses
were able to induce nAbs that inhibited both wt and escape
viruses. Thus, the variant viruses reveal via nAbs a recapitu-
lation of their evolution and exhibit a new sort of coevolu-
tionarily directed connectivity that one might call “arche-
typical”. In some aspects, this recall of genetic history is
reminiscent of findings during influenza virus infections in
the context of preexisting immune memory: after infection
with an escape mutant after antigenic drift, influenza-
immune individuals will generate higher Ab titers against
the influenza surface hemagglutinin experienced during the
original infection than against the mutated hemagglutinin
of the drifted variant. This has been called original anti-
genic sin (35, 36).
Other factors may contribute to the long-term persis-
tence of nAb-resistant viruses, depending on the variant
analyzed. Some variants may have better intrinsic replica-
tion capacities in vivo. Alternatively, changes in cell or tis-
sue tropism, as well as possible differences in resistance to
interferons, may account for the observed enhanced persis-
tence. All these alterations may be the consequence of
some of the documented mutations in the GP1 gene, as
demonstrated at several occasions for different LCMV
strains (37–39). In addition, mutations in other genes can-
not be excluded, particularly on the L strand which en-
codes the viral polymerase and which was not sequenced in
this study.
However, the most important mechanism leading to the
persistence of emerging nAb-escape variants is the induc-
tion of specific CD41 T cell unresponsiveness, as demon-
strated here. The absence of an adequate T helper response
at the moment of viral escape impaired the induction of
new nAb responses against the virus mutants and allowed
them to persist. Interestingly, the primary nAb response in
CD82/2 mice after infection with LCMV-WE was very
potent, despite the fact that the CD41 T cell expansion was
much lower than in normal mice and the helper response
was rapidly lost. Several factors may account for this find-
ing. First, virus-specific B cells, infected through the
LCMV-GP1–recognizing receptor, are not killed in the
absence of CTL responses (40). Second, the antigen load is
much higher in CD82/2 mice. On the other hand, mem-
ory B cell responses may be less dependent on functional T
help (41), explaining how high nAb titers can be main-
tained in CD82/2 mice against the immunizing LCMV-
WE-wt despite vanishing T helper responses.
The CD41 T cell dysfunction in CD82/2 mice does not
affect the overall CD41 T cell population and is only con-
fined to the LCMV-specific compartment. Furthermore, as
exemplified by the adoptive transfer of tg SMARTA sple-
nocytes into LCMV-infected CD82/2 mice, LCMV-spe-
cific CD41 T cell numbers remain equal to levels in unin-
fected control animals for at least 3 wk, indicating that the
cells might undergo a phase of functional unresponsiveness
before being physically deleted.
It has to be emphasized that CD82/2 mice are able to
mount vigorous CD41 T cell responses when infected with
a low dose of a slowly replicating LCMV strain (LCMV-
Armstrong; up to 14% at day 9; reference 21). An influence
of elevated virus titers on the fate of T helper responses is
indicated by the fact that a similar low percentage of
LCMV-specific CD41 T cells was reached during infection
with the clone 13 strain of LCMV (21), which is able to
establish persistent infections in immunocompetent mice
(37). The high viral replication level achieved in CD82/2
mice (but not B6 mice) infected with LCMV-WE is com-
parable to the overwhelming infection of immunocompe-
tent hosts by the rapidly replicating Docile strain of
LCMV, where virus-specific T helper cell loss has also
been shown (19). As CD81 T cells may also contribute
positively to T helper cell responsiveness via bystander fac-
tors (42), their absence in CD82/2 mice might also impact
on the loss of specific CD41 T cells.
Decrease of virus-specific T helper cells seems to be a
critical evolutionary phenomenon which allows the sur-
vival of the host by preventing lethal immunopathology
during persisting noncytopathic virus infection (19). The
molecular mechanisms involved in the loss of T cell func-
tion remain unclear. As hypothesized for the described ex-
haustion of CTLs (24, 43), high antigenic load after wide
viral spread may induce a general activation of all available
virus-specific CD41 T cells. These cells then would die of
activation-induced apoptosis preceded by a period of an-
ergy. Replenishment of virus-specific T helper cells would
not be possible as a consequence of negative T cell selec-
tion in the infected thymus (44). Other contributing factors
like interleukin starvation have been postulated, but their
involvement has not been conclusively demonstrated.
The relevance of this in vivo model of inactivation of
specific CD41 T cells is based on increasing evidence for a
role of T helper cells in the immune control of noncyto-
pathic viral infections, by supporting not only nAb re-
sponses, but also CTLs (45). Studies of LCMV-infected
mice deficient in CD41 T cells either by in vivo treatment
with anti-CD4 monoclonal Ab or by gene targeting have
demonstrated a loss of long-term functional CTL responses
and the enhancement of viral persistence in the absence of
T helper cells (4, 5, 25, 46–49). Low CD41 T cell re-
sponses have also been shown to correlate with high viral
load (50, 51) and with low CTL responses (52) during HIV
infection. Similarly, hepatitis C virus–specific CD41 T cells
seem to be essential not only for initial viral clearance, but303 Ciurea et al.
also for long-term viral control (53). With regard to the
impact of early viral load on subsequent impairment of T
helper responses, it has been recently shown that early sup-
pression of HIV-1 by highly active antiretroviral therapy
may preserve CD41 and CD81 T cell function and may be
associated with immune control (54, 55). The preserved T
helper cell function may allow multiple rounds of nAb-
escape and may therefore lead to the observed broadly
cross-reactive nAb responses in HIV-infected long-term
nonprogressors (56).
Together with earlier observations demonstrating an in-
fluence of nAb-producing B cells on LCMV long-term
control (4, 5, 10, 57), this study provides further evidence
for the interactions between cellular and humoral immune
responses for efficient virus control. However, an adequate
balance between the two arms of the acquired immune sys-
tem is needed in order to avoid virus escape due to virus
variant selection through a unilateral immune response.
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